Patent US4346227A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4346227A Expired / Lapsed US ⏱️ 0.0 years remaining

ML-236B Derivatives and their preparation

Assignee: Sankyo Co Ltd
•
Filing: 1981-06-05
•
Granted: 1982-08-24
•
Expires: 2001-06-05
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Compounds of formula (I): ##STR1## (wherein R represents a group of formula ##STR2## and the corresponding ring-closed lactones, salts (especially alkali metal salts) and esters (especially C 1 -C 5 alkyl esters) thereof may be prepared by subjecting ML-236B, or ML-236B carboxylic acid or a salt or ester thereof to enzymatic hydroxylation, which may be effected by means of microorganisms of the genera Mucor, Rhizopus, Zygorynchus, Circinella, Actinomucor, Gongronella, Phycomyces, Martierella, Pycnoporus, Rhizoctonia, Absidia, Cunninghamella, Syncephalastrum and Streptomyces, or cell-free, enzyme-containing extracts from said microorganisms. The compounds are capable of inhibiting biosynthesis of cholesterol and are thus useful in the treatment of hypercholesteraemia.

Inventors

  • 👤 Akira Terahara
  • 👤 Minoru Tanaka

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 10:15
CPC Classifications
C; C07; C07D; C07D309/00; C07D309/16; C07D309/28; C07D309/30; C12; C12N; C12N1/00; C12N1/20; C12N1/205; C12N1/14; C12N1/145; C12P; C12P17/00; C12P17/02; C12P17/06; C12P7/00; C12P7/62; C12R; C12R2001/00; C12R2001/01; C12R2001/465; C12R2001/645; C12R2001/65; C12R2001/785; C12R2001/845; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/822; Y10S435/886

Claims Analysis

Total Claims: 26
Claim 1
Independent Claim 43 words
Compounds of formula (I): ##STR19## wherein R 1 represents a hydrogen atom or a C 1 -C 5 alkyl group, and R represents a group of the formula ##STR20## and pharmaceutically acceptable salts of the acid when R 1 represents a hydrogen atom.
Claim 2
Dependent Claim 43 words
Compounds of formula (I): ##STR19## wherein R 1 represents a hydrogen atom or a C 1 -C 5 alkyl group, and R represents a group of the formula ##STR20## and pharmaceutically acceptable salts of the acid when R 1 represents a hydrogen atom.
Claim 3
Dependent Claim 41 words
Compounds as claimed in claim 1, having the formula (II) ##STR21## (in which R 1 represents a hydrogen atom or a C 1 -C 5 alkyl group) and pharmaceutically acceptable salts of the acid wherein R 1 represents a hydrogen atom.
Claim 4
Dependent Claim 13 words
Compounds as claimed in claim 2, wherein R 1 represents a hydrogen atom.
Claim 5
Dependent Claim 17 words
Compounds as claimed in claim 2, wherein R 1 represents a C 1 -C 5 alkyl group.
Claim 6
Dependent Claim 13 words
Compounds as claimed in claim 2, wherein R 1 represents a methyl group.
Claim 7
Dependent Claim 13 words
Compounds as claimed in claim 2, in the form of alkali metal salts.
Claim 8
Dependent Claim 13 words
Compounds as claimed in claim 6, in the form of the sodium salt.
Claim 9
Dependent Claim 28 words
Compounds as claimed in claim 2, having the configuration shown in formula (IV): ##STR22## (wherein R 1 is as defined in claim 2) and pharmaceutically acceptable salts thereof.
Claim 10
Dependent Claim 13 words
Compounds as claimed in claim 8, wherein R 1 represents a hydrogen atom.
Claim 11
Dependent Claim 17 words
Compounds as claimed in claim 8, wherein R 1 represents a C 1 -C 5 alkyl group.
Claim 12
Dependent Claim 13 words
Compounds as claimed in claim 8, wherein R 1 represents a methyl group.
Claim 13
Dependent Claim 14 words
Compounds as claimed in claim 8, in the form of the alkali metal salts.
Claim 14
Dependent Claim 13 words
Compounds as claimed in claim 12, in the form of the sodium salt.
Claim 15
Dependent Claim 28 words
Compounds as claimed in claim 2, having the configuration shown in formula (VI): ##STR23## (wherein R 1 is as defined in claim 2) and pharmaceutically acceptable salts thereof.
Claim 16
Dependent Claim 13 words
Compounds as claimed in claim 14, wherein R 1 represents a hydrogen atom.
Claim 17
Dependent Claim 17 words
Compounds as claimed in claim 14, wherein R 1 represents a C 1 -C 5 alkyl group.
Claim 18
Dependent Claim 13 words
Compounds as claimed in claim 14, wherein R 1 represents a methyl group.
Claim 19
Dependent Claim 14 words
Compounds as claimed in claim 14, in the form of the alkali metal salts.
Claim 20
Dependent Claim 13 words
Compounds as claimed in claim 18, in the form of the sodium salt.
Claim 21
Dependent Claim 42 words
Compounds as claimed in claim 1, which have the formula (VIII): ##STR24## (in which R 1 represents a hydrogen atom or a C 1 -C 5 alkyl group) and pharmaceutically acceptable salts of the acid wherein R 1 represents a hydrogen atom.
Claim 22
Dependent Claim 13 words
Compounds as claimed in claim 20, wherein R 1 represents a hydrogen atom.
Claim 23
Dependent Claim 17 words
Compounds as claimed in claim 20, wherein R 1 represents a C 1 -C 5 alkyl group.
Claim 24
Dependent Claim 13 words
Compounds as claimed in claim 20, wherein R 1 represents a methyl group.
Claim 25
Dependent Claim 14 words
Compounds as claimed in claim 20, in the form of the alkali metal salts.
Claim 26
Dependent Claim 13 words
Compounds as claimed in claim 24, in the form of the sodium salt.

References Cited (Backward Citations)

US4137322A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1985-08-23 1986-02-22 1986-08-24 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1989-08-23 1990-02-22 1990-08-24 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1993-08-23 1994-02-22 1994-08-24 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag